Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • CDSCO directs makers...

    CDSCO directs makers of Aceclofenac, Drotaverine Hydrochloride FDC to conduct Active Post Marketing Surveillance on atleast 200 patients

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-09-22T11:30:14+05:30  |  Updated On 19 Dec 2022 6:02 PM IST
    CDSCO directs makers of Aceclofenac, Drotaverine Hydrochloride FDC to conduct Active Post Marketing Surveillance on atleast 200 patients

    New Delhi: Through a recent notification, the Central Drugs Standard Control Organisation(CDSCO) has directed all the manufacturers of Fixed-Dose Combination(FDC) of Aceclofenac 100mg and Drotaverine Hydrochloride 80mg tablet, to conduct Active Post Marketing Surveillance on minimum 200 patients for the treatment of colicky pain due to smooth muscle spasm as per Drugs and Cosmetics Rules.


    The FDC of Aceclofenac 100mg + Drotaverine Hydrochloride 80mg tablet was initially approved by CDSCO in favour of Themis Medicare. Based on the 59th report of Parliamentary Standing Committee (PSC) it was decided that FDC of Acedofenac 100mg + Drotaverine Hydrochloride 80mg tablet would be referred to New Drug Advisory Committee (NDAC)/Subject Expert Committee (SEC) for examination and review related to its continued marketing and updation of product monograph in light of recent knowledge and regulatory changes in overseas.


    Accordingly, the matter was discussed in a series of meetings of the NDAC/SEC. Based on the recommendations of Subject Expert Committee, it was decided that the FDC of Aceclofenac 100mg + Drotaverine Hydrochloride 80mg tablet shall be indicated for the treatment of "colicky pain due to smooth muscle spasm" for its continued marketing. However, manufacturers of this product shall conduct clinical trials.


    As per the recommendations of Subject Expert Committee, Themis Medicare was asked to revise the indication and submit the clinical trial protocol for conducting the study. However, after a series of communications, Themis Medicare finally surrendered the product license.


    Recently, the proposal was again re-deliberated in 60th SEC (Reproductive & Urology) with a current status. The committee reviewed its earlier decision for conducting the Phase-IV clinical trial on the FDC.


    After detailed deliberation, the committee recommended that the firm(s) may be directed to conduct Active Post Marketing Surveillance in minimum 200 patients and the study should include patients of Primary dysmenorrhea, biliary colic and ureteric colic. The study should be completed within one year and the results of the study should be placed before the committee for further review.



    In view of above, facts and circumstances, it has been directed to all the manufacturers of said FDC under relevant jurisdiction to conduct Active Post Marketing Surveillance on minimum 200 patients for the treatment of colicky pain due to smooth muscle spasm as per Drugs and Cosmetics Rules. The study should include patients of Primary dysmenorrhea, biliary colic, ureteric colic and report of the same shall be submitted to this Directorate within one year for further review by the Subject Expert Committee.


    Also Read: 328 FDC Medicines banned over safety concern: Health Ministry Notification

    aceclofenacbiliary colicCDSCOCentral Drugs Standard Control OrganisationClinical Trialcolicky painDCRDrotaverineDrugs n Cosmetics RulesdysmenorrheaFDCFDCsFixed Dose CombinationHydrochlorideMarketing Surveillancemuscle spasmParliamentary Standing Committeepharmapharma newspharma news indiaphase 4 trialPSCSECSEC Committeesubjects expert committeeureteric colicurology

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok